Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stroke: antithrombin versus antiplatelet therapy.

M M Bednar1

  • 1Clinical Research CNS, Central Research Division, Pfizer, Inc., Eastern Point Road, PO Box 8030, Groton, CT 06340-8030, USA. martin_m_bednar@groton.pfizer.com

Expert Opinion on Investigational Drugs
|November 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242.

Molecular psychiatry·2017
Same author

Report of the task force on designing clinical trials in early (predementia) AD.

Neurology·2010
Same author

The effect of vasodilators on aspirin-induced antagonism of t-PA thrombolysis.

Neurological research·2001
Same author

The QT interval.

Progress in cardiovascular diseases·2001
Same author

16(R)-hydroxyeicosatetraenoic acid, a novel cytochrome P450 product of arachidonic acid, suppresses activation of human polymorphonuclear leukocyte and reduces intracranial pressure in a rabbit model of thromboembolic stroke.

Neurosurgery·2000
Same author

16(R)-hydroxy-5,8,11,14-eicosatetraenoic acid, a new arachidonate metabolite in human polymorphonuclear leukocytes.

Biochemical pharmacology·2000
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

New stroke therapies are needed as thrombolytics have limitations. Antiplatelet and antithrombin agents show promise, but challenges remain in optimizing their use for acute and secondary stroke prevention.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Thrombolytic therapy improves acute stroke outcomes but has limited use.
  • Alternative and complementary therapies are crucial for stroke management.
  • Antithrombin and antiplatelet agents are promising but face challenges.

Purpose of the Study:

  • To explore advancements in antithrombin and antiplatelet therapies for stroke.
  • To address pharmacokinetic and pharmacodynamic challenges in stroke treatment.
  • To review current and future strategies for acute, primary, and secondary stroke therapy.

Main Methods:

  • Review of current clinical trials for glycoprotein IIb/IIIa inhibitors.
  • Examination of antithrombin therapies targeting thrombin and Factor Xa.

Related Experiment Videos

  • Focus on understanding drug effects on platelet function, coagulation, endothelium, and brain parenchyma.

    • Main Results:

    • Antiplatelet therapy offers modest benefits in acute and secondary stroke prevention.
    • Adverse events from antithrombin therapy have limited its clinical utility.
    • Ongoing research explores novel inhibitors and combination therapies.

    Conclusions:

    • Optimizing antithrombin and antiplatelet agents is key to improving stroke treatment.
    • Future therapies require a comprehensive understanding of drug mechanisms.
    • Advances aim to maintain cerebral blood flow, blood-brain barrier integrity, and neuronal function.